Study summary
Tirzepatide protected the heart at least as well as dulaglutide
12.2%had a heart attack, stroke or heart death, vs 13.1% with dulaglutide
What was tested
Tirzepatide against dulaglutide (a GLP-1 drug already shown to lower heart risk) in people with type 2 diabetes and heart or blood vessel disease.
What they found
- Heart attack, stroke or cardiovascular death occurred in 12.2% vs 13.1%.
- Tirzepatide met the goal of being no worse; the 8% lower risk was not statistically proven superior.
- Stomach side effects were more common with tirzepatide.
What it means
Tirzepatide can be used for heart protection in type 2 diabetes.
Last reviewed 2026-11-16 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.